Ampio Pharma Reports Additional Positive Results From SPRING Study Of Ampion

(RTTNews) - Ampio Pharmaceuticals Inc. (AMPE) announced additional positive results from the SPRING study of Ampion for the treatment of osteoarthritis of the knee. Patients treated with a single intra-articular injection of Ampion achieved a clinically meaningful reduction in pain, the company said. Ampio announced on August 14, that the SPRING study met its primary and key secondary endpoints.

The newly announced positive results include: The reduction in pain compared to the vehicle control was also significant across/over the whole twelve-week period and not just at the 12 weeks end point; The study demonstrated that a single intra-articular injection of Ampion resulted in a clinically and statistically significant reduction in pain, corresponding to a 42.3% improvement in pain at 12 weeks in patients treated with Ampion.